Ignite Creation Date:
2024-05-06 @ 3:32 PM
Last Modification Date:
2024-10-26 @ 1:51 PM
Study NCT ID:
NCT04662294
Status:
RECRUITING
Last Update Posted:
2021-11-04
First Post:
2020-10-22
Brief Title:
CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
Sponsor:
Zhejiang University
Organization:
Zhejiang University
Study Overview
Official Title:
Clinical Trial for the Safety and Efficacy of CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
Status:
RECRUITING
Status Verified Date:
2020-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A Study of CD 70 CAR T for patients with CD70 positive malignant hematologic diseases
Detailed Description:
This is a single arm open-label single-center study This study is indicated for CD 70 CAR T for patients with CD70 positive malignant hematologic diseases The selections of dose levels and the number of subjects are based on clinical trials of similar foreign products 108 patients will be enrolled Primary objective is to explore the safetymain consideration is dose-related safety
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None